Long-Term Clinical Outcomes of Polymer-Free Sirolimus-Eluting Stent and Polymer-Coated Sirolimus-Eluting Stent in Patients with Type 2 Diabetes

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2024 Nov 18

PMID 39553456

Authors

Ou Yang

Yuhuan Teng

Ruoxi Zhang

Jie Qu

Affiliations

Soon will be listed here.

Abstract

Introduction: Polymer-free sirolimus-eluting stent (PF-SES) possess multiple properties improving targeted drug elution and in-stent reendothelialization without the presence of polymers. The long-term clinical performance comparison between PF-SES and the latest generation polymer-coated sirolimus-eluting stents (SES), particularly regarding intravascular imaging assessment and in the type 2 diabetes mellitus (DM) population, remains unexplored.

Methods: We conducted a retrospective study involving 2646 diabetes patients meeting coronary artery disease (CAD) criteria underwent coronary stents in the real-world. All patients were divided into the PF-SES group and the SES group. Optical coherence tomography (OCT) was used to evaluate the imaging characteristics of in-stent reendothelialization. Patient information between the two groups was systematically compared in hospital and at 5-year follow-up.

Results: In terms of basic characteristics, the proportion of current smoker and stable angina patients in the PF-SES group was significantly higher than that in the SES group. The PF-SES group exhibited significantly higher rate of left anterior descending (LAD) lesion and more stents per patients compared to the SES group. The value of minimum lumen area (MLA), neointimal area (NA) and neointimal thickness (NT) were higher in the PF-SES group. Additionally, the occurrence rates of heterogeneous, lipid layer, intimal tears, thrombi, and micro-vessels were notably lower in the PF-SES group compared to the SES group. A higher all-cause mortality was observed in the SES cohort.

Discussion: PF-SES could effectively improve in-stent reendothelialization in patients with type 2 DM, with positive effects on survival rate and may, therefore, be considered as an alternative treatment option for improving clinical long-term outcomes.

References

Wessely R . New drug-eluting stent concepts. Nat Rev Cardiol. 2010; 7(4):194-203. DOI: 10.1038/nrcardio.2010.14. View

Iaccarino D, Politi L, Rossi R, Sgura F, Monopoli D, Modena M . Rationale and study design of the OISTER trial: optical coherence tomography evaluation of stent struts re-endothelialization in patients with non-ST-elevation acute coronary syndromes--a comparison of the intrEpide tRapidil eluting stent vs. taxus.... J Cardiovasc Med (Hagerstown). 2010; 11(7):536-43. DOI: 10.2459/JCM.0b013e32833499c4. View

Schwartz R, Chronos N, Virmani R . Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol. 2004; 44(7):1373-85. DOI: 10.1016/j.jacc.2004.04.060. View

Bukka M, Rednam P, Sinha M . Drug-eluting balloon: design, technology and clinical aspects. Biomed Mater. 2017; 13(3):032001. DOI: 10.1088/1748-605X/aaa0aa. View

Joner M, Finn A, Farb A, Mont E, Kolodgie F, Ladich E . Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006; 48(1):193-202. DOI: 10.1016/j.jacc.2006.03.042. View

. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2021; 45(Suppl 1):S17-S38. DOI: 10.2337/dc22-S002. View

Hu F, Meigs J, Li T, Rifai N, Manson J . Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes. 2004; 53(3):693-700. DOI: 10.2337/diabetes.53.3.693. View

Mori H, Gupta A, Torii S, Harari E, Jinnouchi H, Virmani R . Clinical implications of blood-material interaction and drug eluting stent polymers in review. Expert Rev Med Devices. 2017; 14(9):707-716. DOI: 10.1080/17434440.2017.1363646. View

Dehghan A, Kardys I, de Maat M, Uitterlinden A, Sijbrands E, Bootsma A . Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes. 2007; 56(3):872-8. DOI: 10.2337/db06-0922. View

10.

Rieber J, Meissner O, Babaryka G, Reim S, Oswald M, Koenig A . Diagnostic accuracy of optical coherence tomography and intravascular ultrasound for the detection and characterization of atherosclerotic plaque composition in ex-vivo coronary specimens: a comparison with histology. Coron Artery Dis. 2006; 17(5):425-30. DOI: 10.1097/00019501-200608000-00005. View

11.

Hezi-Yamit A, Sullivan C, Wong J, David L, Chen M, Cheng P . Impact of polymer hydrophilicity on biocompatibility: implication for DES polymer design. J Biomed Mater Res A. 2008; 90(1):133-41. DOI: 10.1002/jbm.a.32057. View

12.

Frohlich M, Imhof A, Berg G, Hutchinson W, Pepys M, Boeing H . Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care. 2000; 23(12):1835-9. DOI: 10.2337/diacare.23.12.1835. View

13.

Tada T, Byrne R, Simunovic I, King L, Cassese S, Joner M . Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv. 2013; 6(12):1267-74. DOI: 10.1016/j.jcin.2013.06.015. View

14.

Costa R, Abizaid A, Mehran R, Schofer J, Schuler G, Hauptmann K . Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions: 4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial. JACC Cardiovasc Interv. 2016; 9(1):51-64. DOI: 10.1016/j.jcin.2015.09.008. View

15.

Otsuka F, Byrne R, Yahagi K, Mori H, Ladich E, Fowler D . Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J. 2015; 36(32):2147-59. DOI: 10.1093/eurheartj/ehv205. View

16.

Pradhan A, Manson J, Rifai N, Buring J, Ridker P . C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001; 286(3):327-34. DOI: 10.1001/jama.286.3.327. View

17.

Jimenez-Valero S, Moreno R, Sanchez-Recalde A . Very late drug-eluting stent thrombosis related to incomplete stent endothelialization: in-vivo demonstration by optical coherence tomography. J Invasive Cardiol. 2009; 21(9):488-90. View

18.

Levine G, Bates E, Bittl J, Brindis R, Fihn S, Fleisher L . 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update.... Circulation. 2016; 134(10):e123-55. DOI: 10.1161/CIR.0000000000000404. View

19.

Kato K, Yonetsu T, Kim S, Xing L, Lee H, McNulty I . Nonculprit plaques in patients with acute coronary syndromes have more vulnerable features compared with those with non-acute coronary syndromes: a 3-vessel optical coherence tomography study. Circ Cardiovasc Imaging. 2012; 5(4):433-40. DOI: 10.1161/CIRCIMAGING.112.973701. View

20.

Stumvoll M, Goldstein B, van Haeften T . Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005; 365(9467):1333-46. DOI: 10.1016/S0140-6736(05)61032-X. View